Full text is available at the source.
Abstract
CRISPR/Cas9 genome-editing technologies may offer innovative strategies to address genetic alterations in glioblastoma multiforme (GBM).
- GBM is characterized by rapid growth and resistance to existing therapies, leading to poor clinical outcomes.
- Key molecular targets associated with GBM include genes like EGFR, PTEN, and TP53.
- Emerging CRISPR applications are being explored in preclinical models and clinical trials for GBM treatment.
- Major barriers to the translation of CRISPR technologies in GBM include off-target effects and delivery challenges across the blood-brain barrier.
- Advanced delivery systems, such as lipid nanoparticles and DNA nanostructures, are being developed to enhance the precision and safety of gene editing in the central nervous system.
Simplified